Market Overview

Cushing's Syndrome | A Pipeline Analysis Report 2018 | Technavio


Technavio has announced their latest pipeline analysis report on the Cushing's
syndrome market
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat Cushing's syndrome.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for Cushing's syndrome, includ ...

Technavio has published a new report on the drug development pipeline for Cushing's syndrome, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Cushing's syndrome: Market overview

Cushing's syndrome results from the long-term exposure to cortisol.
Cortisol is the body's stress hormone. The concentration of cortisol can
increase in the body either due to cortisol supplement or because of the
overproduction of cortisol. Untreated Cushing's syndrome can lead to
high blood pressure, bone loss, and sometimes type 2 diabetes. The
disease can be classified into two types including, Endogenous Cushing's
syndrome and Exogenous Cushing's syndrome. Endogenous glucocorticoid
overproduction or hypercortisolism can be dependent on or independent of
adrenocorticotropic hormone (ACTH). While Exogenous Cushing's syndrome
is found in individuals taking cortisol-like medications such as
prednisone. It is a temporary condition and goes away once the intake of
cortisol-like medications stops.

According to a senior market research analyst at Technavio, "Research
by National Institutes of Health states that Cushing's syndrome most
often affects adults aged 30-50 years but can also occur in children.
Cushing's syndrome affects about three times as many women as men. More
than 10 million Americans take glucocorticoids each year, but it is not
known how many of them develop Cushing's syndrome."

Cushing's syndrome: Segmentation analysis

This pipeline analysis report segments the Cushing's syndrome market
based on therapies employed (monotherapy), RoA (oral), therapeutic
modality (small molecule, and microRNA), targets (CYP11B1,
glucocorticoid receptor, 11beta-hydroxylase,
17alpha-hydroxylase/17,20-lyase, and steroid 21-hydroxylase, ACAT1,
11beta-hydroxylase and aldosterone synthase, steroidogenic factor 1, and
glucose-6-phosphate dehydrogenase), MoA (CYP11B1 inhibitor,
glucocorticoid receptor antagonist, 11beta-hydroxylase,
17alpha-hydroxylase/17,20-lyase, and steroid 21-hydroxylase inhibitor,
ACAT1 inhibitor, 11beta-hydroxylase and aldosterone synthase inhibitor,
steroidogenic factor 1 antagonist, and glucose-6-phosphate dehydrogenase
inhibitor), geographical segmentation (Italy, the Netherlands, and
Hungary) and recruitment status (active, not recruiting, and
recruiting). It provides an in-depth analysis of the prominent factors
influencing the market, including drivers, opportunities, trends, and
industry-specific challenges.

Based on therapeutic modality, around 80% of the molecules that are
being investigated for the treatment of Cushing's syndrome are small

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!